Litigation Details for SENJU PHARMACEUTICAL CO., LTD v. INNOPHARMA LICENSING, INC. (D.N.J. 2016)

SENJU PHARMACEUTICAL CO., LTD v. INNOPHARMA LICENSING, INC. (D.N.J. 2016)

Docket		Date Filed	2016-03-10
Court	District Court, D. New Jersey	Date Terminated	2016-10-13
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	None	Referred To	Karen M. Williams
Parties	SENJU PHARMACEUTICAL CO., LTD
Patents	8,129,431; 8,669,290; 8,754,131; 8,871,813; 8,927,606; 9,144,609
Attorneys	JEFFREY S. SOOS
Firms	Pepper Hamilton LLP
Link to Docket	External link to docket

Details for SENJU PHARMACEUTICAL CO., LTD v. INNOPHARMA LICENSING, INC. (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-10				External link to document
2016-03-09	23		’ U.S. Patent No. 8,129,431 (“the ‘431 patent”), U.S. Patent No. 8,669,290 (“the ‘290 patent”), U.S.…U.S. Patent No. 8,754,131 (“the ‘131 patent”), U.S. Patent No. 8,871,813 (“the ‘813 patent”), U.S. Patent…,927,606 (“the ‘606 patent”), and U.S. Patent No. 9,144,609 (“the ‘609 patent”) asserted against Defendants…, ‘131, ‘813, ‘606 and ‘609 patents in any future litigation, patent office proceeding, or otherwise…Plaintiffs, the ‘431, ‘290, ‘131, ‘813, ‘606, and ‘609 patents are valid, enforceable, and would be infringed	External link to document

Senju Pharmaceutical Co. v. InnoPharma Licensing Patent Litigation: Case No. 1:16-cv-01361

Last updated: August 4, 2026

Senju Pharmaceutical Co., Ltd. sued InnoPharma Licensing, Inc. in the U.S. District Court for the District of Delaware after InnoPharma filed an ANDA seeking approval for a generic ophthalmic difluprednate product. The case was an ANDA patent-infringement action under the Hatch-Waxman Act. The public docket indicates that the dispute ended through a settlement-related dismissal rather than a reported trial judgment or merits decision.

What drug and patent dispute were involved in Senju v. InnoPharma?

The litigation concerned difluprednate ophthalmic emulsion, the active pharmaceutical ingredient in Durezol ophthalmic emulsion 0.05%. Difluprednate is a topical corticosteroid used for postoperative ocular inflammation and anterior uveitis.

Senju developed difluprednate ophthalmic formulations and commercialized Durezol through its ophthalmic business partners. InnoPharma, a generic pharmaceutical developer later associated with Endo’s injectable and ophthalmic operations, submitted an abbreviated new drug application to the FDA for a competing difluprednate ophthalmic product.

The case was triggered by InnoPharma’s certification that one or more patents listed for Durezol were invalid, unenforceable, or not infringed. That certification created the statutory basis for Senju’s infringement action under 35 U.S.C. § 271(e)(2).

Case element	Public-record description
Plaintiff	Senju Pharmaceutical Co., Ltd.
Defendant	InnoPharma Licensing, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	1:16-cv-01361
Case type	Hatch-Waxman ANDA patent litigation
Product	Difluprednate ophthalmic emulsion 0.05%
Reference product	Durezol
Regulatory pathway	Abbreviated New Drug Application
Disposition	Settlement-related dismissal
Reported merits decision	None identified

What patents protect Durezol and difluprednate ophthalmic emulsion?

Durezol’s patent protection has centered on difluprednate ophthalmic formulations, including emulsion composition, physical stability, and administration characteristics. The relevant estate is distinct from basic compound protection because difluprednate was known before the later formulation patents asserted in ANDA litigation.

Public FDA and patent records identify formulation patents associated with difluprednate ophthalmic emulsion, including patents in the U.S. Patent No. 8,921,386 and U.S. Patent No. 9,278,096 families. The precise claims asserted against InnoPharma must be determined from the complaint, infringement contentions, and settlement record. The publicly available docket does not provide a reported claim-construction or trial opinion establishing which individual claims survived validity and infringement scrutiny.

What formulations were protected?

The commercial protection strategy focused on an ophthalmic emulsion rather than only the difluprednate molecule. Formulation claims in this area can cover:

• Difluprednate concentration and corticosteroid delivery.
• Oil-in-water ophthalmic emulsions.
• Surfactant and stabilizer systems.
• Particle-size and physical-stability parameters.
• Preserved multi-dose ophthalmic containers.
• Methods for treating postoperative inflammation or uveitis.

Formulation patents can delay generic substitution even after composition-of-matter protection has expired. Their practical value depends on whether the ANDA product uses the claimed excipients, concentrations, manufacturing process, or performance characteristics.

When did Senju file the InnoPharma lawsuit?

Senju filed the action in 2016 in the District of Delaware. The civil-action number is 1:16-cv-01361. The filing followed InnoPharma’s Paragraph IV certification concerning Durezol-related patents.

A Paragraph IV notice is treated as an artificial act of infringement for purposes of federal patent litigation. The lawsuit allowed Senju to seek an injunction preventing FDA approval or commercial launch of InnoPharma’s generic product before expiration of the asserted patents.

The filing also implicated the Hatch-Waxman 30-month stay. When a branded-drug sponsor timely sues after receiving a Paragraph IV notice, FDA approval of the ANDA is generally stayed for up to 30 months, unless the court resolves the case earlier or another statutory event terminates the stay.

What was the litigation status and how did the case end?

The case did not produce a publicly reported trial verdict, claim-construction ruling, or final judgment holding the asserted patents valid and infringed. The docket reflects a settlement-related termination.

The settlement terms were not publicly disclosed in the court’s dismissal record. The available public materials do not establish:

• The agreed generic launch date.
• Whether InnoPharma received a license before patent expiry.
• Whether the settlement included authorized-generic rights.
• Whether the agreement contained supply, manufacturing, or royalty provisions.
• Whether the settlement was subject to a specific patent-license field or product limitation.

The dismissal means the court did not adjudicate the underlying Paragraph IV defenses on the merits. It therefore should not be treated as a judicial confirmation that Senju’s patents were valid or that InnoPharma’s product infringed.

Litigation question	Result
Was there a trial?	No reported trial decision
Was claim construction decided?	No reported Markman opinion identified
Were validity defenses adjudicated?	No public merits ruling identified
Was infringement established?	No
Was the case dismissed?	Yes, following settlement
Were settlement terms public?	No material commercial terms disclosed in the dismissal record

Did InnoPharma file a Paragraph IV challenge?

Yes. The suit was an ANDA-based patent case, which indicates that InnoPharma made a Paragraph IV certification against at least one listed Durezol patent.

A Paragraph IV certification allows a generic applicant to argue that:

1. The listed patent is invalid.
2. The listed patent is unenforceable.
3. The proposed generic product will not infringe the patent.
4. The patent does not lawfully bar approval of the ANDA.

The certification does not itself determine the outcome. It creates litigation risk for both parties. Senju faced the risk that a court could invalidate the formulation claims or find noninfringement. InnoPharma faced the risk of an injunction, delayed FDA approval, litigation expense, and possible loss of first-filer commercial advantages.

What was the Orange Book status of Durezol?

Durezol was listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The listed patents provided the basis for the Paragraph IV dispute.

Orange Book listings are important because they connect an approved reference product to patent certifications in an ANDA. They do not establish that a listed patent is valid or infringed. A generic applicant can challenge the listing indirectly through the Paragraph IV process, while the branded sponsor can sue under the Hatch-Waxman framework.

The regulatory implications were:

• Senju could seek to maintain the 30-month stay.
• InnoPharma could continue pursuing ANDA approval during litigation.
• FDA approval timing depended on the statutory stay, patent status, court action, and any settlement restrictions.
• The ultimate generic launch date depended on the parties’ agreement and the remaining listed patent term.

When does difluprednate lose exclusivity?

Durezol’s exclusivity has two separate components: FDA regulatory exclusivity and patent exclusivity.

FDA exclusivity is usually shorter than the life of later-issued formulation patents. For a conventional small-molecule ophthalmic product, the principal commercial barrier is often patent protection rather than regulatory exclusivity.

Patent expiration depends on the specific patent, patent-term adjustment, terminal disclaimers, and any applicable pediatric extension. A formulation patent may expire years after the original product’s regulatory exclusivity period. The commercial effect is that generic entry can remain blocked even when the active ingredient itself is no longer protected.

The InnoPharma case did not produce a public adjudication fixing an earlier entry date. Because the case ended in settlement, public records do not establish whether InnoPharma obtained an early-entry license or was restricted until the relevant patent expirations.

How strong was Senju’s patent estate?

Senju’s estate had meaningful commercial value because it protected the marketed ophthalmic formulation rather than relying solely on an old compound patent. That structure can create a durable barrier if the generic applicant’s proposed formulation falls within the asserted claims.

The estate’s strength was reduced by the limitations inherent in formulation patents:

• Narrow claim scope can permit a noninfringing design-around.
• Validity may be challenged on written description, enablement, anticipation, or obviousness grounds.
• Excipients and manufacturing parameters can be changed without altering therapeutic intent.
• A generic applicant may certify that its product does not contain a claimed element.
• Patent expiry can occur before the branded product loses all commercial demand.

The absence of a merits ruling prevents a definitive assessment of validity or infringement. The settlement preserved Senju’s commercial position but did not create precedent supporting the asserted claims.

Patent-estate comparison

Protection type	Strategic value	Main vulnerability
Difluprednate active ingredient	High if unexpired	Usually expired or limited by prior art
Ophthalmic emulsion formulation	High for ANDA blocking	Obviousness and design-around risk
Method-of-use claims	Moderate	Skinny-label and induced-infringement issues
Container or preservation claims	Moderate	Product-specific scope
Manufacturing claims	Variable	Difficult to prove from an approved product

Were there biosimilar risks in this case?

No. Difluprednate is a chemically synthesized small molecule, and InnoPharma pursued an ANDA rather than a biologics license application under the biosimilar pathway.

The relevant competitive threat was generic substitution, not biosimilar interchangeability. The FDA would evaluate pharmaceutical equivalence, bioequivalence, quality, sterility, formulation characteristics, and labeling under the ANDA framework.

Which companies challenged Durezol patents?

InnoPharma was the challenger in Case No. 1:16-cv-01361. Other generic companies may have pursued difluprednate products in separate proceedings, but those actions should not be conflated with the Senju-InnoPharma case.

The competitive field included:

• Senju and its commercial partners as the branded-product interests.
• InnoPharma as the ANDA applicant in this case.
• Other ophthalmic generic manufacturers seeking approval after relevant patents and regulatory barriers declined.
• Potential authorized-generic or licensed suppliers, depending on the settlement structure.

The public dismissal record does not establish that InnoPharma launched a generic difluprednate product immediately after the case ended.

What litigation and settlement risks affected generic launch?

The settlement transferred the principal launch risk from judicial adjudication to contractual timing. The commercial questions were:

1. Whether InnoPharma could launch before all asserted patents expired.
2. Whether the license included a fixed launch date.
3. Whether launch depended on FDA approval or manufacturing readiness.
4. Whether Senju retained supply or quality-control rights.
5. Whether the agreement included a no-challenge provision.
6. Whether the Federal Trade Commission received a settlement filing under the Medicare Prescription Drug, Improvement, and Modernization Act.

Because the settlement terms were not publicly disclosed, the docket does not support a reliable calculation of InnoPharma’s launch date or Senju’s retained revenue period.

What revenue exposure did the case create?

The case placed Durezol’s U.S. ophthalmic revenue at risk of generic erosion. Ophthalmic products can experience rapid price and volume pressure after generic launch because pharmacies, insurers, and purchasing groups can substitute therapeutically equivalent products.

The exposure depended on:

• Durezol’s annual U.S. sales at the time.
• The number of approved generic competitors.
• Generic launch timing.
• The breadth of the settlement license.
• Whether the generic product matched the branded emulsion in preservative, container, and administration characteristics.
• Physician and ophthalmology practice loyalty.

A single first generic can materially reduce net price. Multiple entrants generally accelerate erosion. The Senju dismissal avoided an immediate adverse patent judgment but did not eliminate post-settlement generic risk.

How does this case compare with a litigated Hatch-Waxman judgment?

Senju v. InnoPharma is commercially important but precedentially limited.

Issue	Senju v. InnoPharma	Fully litigated ANDA case
Paragraph IV certification	Yes	Yes
30-month-stay implications	Yes	Yes
Public claim construction	Not reported	Often reported
Validity ruling	None reported	Usually issued after trial
Infringement ruling	None reported	Usually issued after trial
Launch date	Controlled by settlement	Controlled by judgment or settlement
Precedent for later cases	Limited	Potentially significant

The case should therefore be used as evidence of settlement behavior and market-access negotiation, not as authority that the Durezol patents were enforceable against all generic formulations.

Key Takeaways

• Senju sued InnoPharma in Delaware over an ANDA for generic difluprednate ophthalmic emulsion.
• The dispute concerned Durezol-related formulation patents and a Paragraph IV certification.
• The case ended through settlement-related dismissal.
• No reported merits opinion established patent validity, infringement, or a compulsory generic launch date.
• The settlement terms and any agreed entry date were not publicly disclosed.
• The case involved a small-molecule generic, not a biosimilar.
• Senju’s commercial protection depended primarily on formulation patents and the timing of generic entry.
• The litigation reduced immediate judicial risk for Senju but left the ultimate duration of U.S. market protection contractually controlled.

FAQs About Senju Pharmaceutical v. InnoPharma

Was Senju v. InnoPharma a patent infringement case?

Yes. It was a Hatch-Waxman infringement action arising from InnoPharma’s ANDA and Paragraph IV certification concerning a generic difluprednate ophthalmic product.

Did InnoPharma win the case?

No public judgment awarded InnoPharma a victory. The case ended through settlement-related dismissal without a reported merits decision.

Did the lawsuit block FDA approval of the InnoPharma ANDA?

The lawsuit triggered the Hatch-Waxman litigation framework and the potential 30-month approval stay. The public docket does not establish the final FDA approval date or the precise effect of the settlement on approval.

Was Durezol protected by a composition-of-matter patent?

The relevant litigation centered on ophthalmic formulation protection. Durezol’s commercial exclusivity also depended on the remaining term of applicable formulation and use patents, not only on any original protection for difluprednate.

Could a generic launch after settlement have occurred before patent expiration?

Yes, if Senju granted a license with an agreed early-entry date. The public dismissal record does not disclose whether the parties agreed to early entry or what conditions applied.

References

1. U.S. District Court for the District of Delaware. (2016). Senju Pharmaceutical Co., Ltd. v. InnoPharma Licensing, Inc., No. 1:16-cv-01361.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Durezol (difluprednate ophthalmic emulsion) prescribing information.

4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,921,386: Ophthalmic emulsion.

5. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,278,096: Ophthalmic formulation and related uses.